Biogen Reports observational Data for Bimekizumab in Breast cancer

Biogen today announced observational results for bimekizumab in patients with breast cancer. The study demonstrated that bimekizumab improves functional outcomes compared to standard of care or placebo. These results provide important insights into the treatment of breast cancer and support the continued development of bimekizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.